Document Detail

Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer.
MedLine Citation:
PMID:  20605315     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Prostate cancer (PCa) is the most common malignancy in males in Western countries. Despite improvements in standard treatments such as surgery, radiotherapy, and chemotherapy, many patients still progress to advanced stages. Recent clinical trials have shown encouraging results regarding the application of angiogenic inhibitors in the treatment of angiogenesis-dependent diseases, paving the way for novel PCa therapies.
OBJECTIVE: To identify new antiangiogenic compounds and examine their therapeutic potential in models of PCa.
DESIGN, SETTING, AND PARTICIPANTS: We performed a chemical genetic screen in developing zebrafish embryos to identify small molecules inhibiting zebrafish angiogenesis. Transgenic Tg(flk1:EGFP) zebrafish embryos were used in the screening of the Spectrum Collection compound library. Subsequently, the antiangiogenic mechanism of an identified lead compound, rosuvastatin, was studied by conducting endothelial cell function assays and examining antitumor efficacy in a PCa xenograft mouse model. MEASUREMENTS, RESULTS AND LIMITATIONS: Seven lead compounds, including isorotenone, dihydromunduletone, aristolochic acid, simvastatin, mevastatin, lovastatin, and rosuvastatin, were identified to inhibit the growth of the zebrafish intersegmental vessels. Of these seven leads, rosuvastatin was further evaluated for its antiangiogenic mechanism and anticancer efficacy. Rosuvastatin decreased the viability of the human umbilical endothelial cells (HUVECs) (one-half inhibitory concentration: 5.87 microM) by inducing G(1) phase arrest and promoting apoptosis. Moreover, rosuvastatin remarkably inhibited the migration of HUVECs and dose-dependently inhibited the HUVEC capillary-like tube formation in vitro. Furthermore, we demonstrated that rosuvastatin suppressed xenografted PPC-1 prostate tumors in nonobese diabetic severe combined immunodeficiency (NOD-SCID) mice associated with decreased microvessel density (MVD) and tumor cell apoptosis.
CONCLUSIONS: Collectively, our data suggest that rosuvastatin possesses antiangiogenic and antitumor activities and has therapeutic potential for the treatment of PCa. This study represents the first zebrafish antiangiogenic chemical genetic screen to identify a lead compound that targets cancer angiogenesis.
Chunyang Wang; Weiyang Tao; Youdong Wang; Jennifer Bikow; Bingxin Lu; Armand Keating; Subodh Verma; Thomas G Parker; Ruifa Han; Xiao-Yan Wen
Related Documents :
23888955 - Comprehensive analysis for histone acetylation of human colon cancer cells treated with...
20337765 - Identification of native bacillus thuringiensis strain from south india having specific...
8023045 - Discrimination techniques applied to the nci in vitro anti-tumour drug screen: predicti...
21103975 - In vitro and in vivo evidence for the importance of breast cancer resistance protein tr...
19488725 - Formulation/preparation of functionalized nanoparticles for in vivo targeted drug deliv...
18770865 - Why do large breast cancers still present in a population offered screening?
Publication Detail:
Type:  Journal Article     Date:  2010-05-22
Journal Detail:
Title:  European urology     Volume:  58     ISSN:  1873-7560     ISO Abbreviation:  Eur. Urol.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-09     Completed Date:  2011-01-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7512719     Medline TA:  Eur Urol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  418-26     Citation Subset:  IM    
Copyright Information:
(c) 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Keenan Research Center, Li Ka Shing Knowledge Institute, St. Michael's Hospital and Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / pharmacology*,  therapeutic use*
Drug Screening Assays, Antitumor
Fluorobenzenes / pharmacology*,  therapeutic use*
Mice, SCID
Neovascularization, Pathologic / drug therapy
Prostatic Neoplasms / blood supply*,  drug therapy*
Pyrimidines / pharmacology*,  therapeutic use*
Sulfonamides / pharmacology*,  therapeutic use*
Tumor Cells, Cultured
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Fluorobenzenes; 0/Pyrimidines; 0/Sulfonamides; 287714-41-4/rosuvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Can conjunctival provocation test facilitate the diagnosis of food allergy in children?
Next Document:  GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment...